Evidence map›Paper›PMID 38252943›Full record

ArticleAnnals of internal medicine2024

Talking With Patients About the New Anti-amyloid Alzheimer Disease Medications.

Catherine A Sarkisian, Artem Romanov, John N Mafi

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Observational
  2. Review
  3. Scaling Alzheimer's Care: The Case for Specialized Treatment Clinics.Journal of the American Geriatrics Society · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Catherine A SarkisianDivision of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA, and Geriatrics Research Education and Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, California (C.A.S.).ORCID 0000-0003-2768-2323
Artem RomanovDivision of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California (A.R.).
John N MafiDivision of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, and RAND Corporation, Santa Monica, California (J.N.M.).

Funding

UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
Identifying Approaches to Measure and Reduce Harmful, Low-Value Care Among Older Americans with Mild Cognitive Impairment and DementiaR01AG070017 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MAFI, JOHN N. · 2021 to 2025
$2.6M
Midcareer Award in Patient-Oriented Community-Academic Partnered Aging ResearchK24AG047899 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SARKISIAN, CATHERINE A · 2014 to 2025
$2.0M
NCRR NIH HHS UL1 RR033176NIA NIH HHS K24 AG047899NIA NIH HHS R01 AG070017
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainHumansAmyloid beta-Peptides

Identifiers

PMID38252943
PMCPMC11249391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.